质子泵抑制剂审方规则专家共识

2022-04-26 重庆市医院协会药事管理专业委员会 中国药房

为进一步规范质子泵抑制剂的临床应用,为处方适宜性审核提供参考,重庆市医院协会药事管理专业委员根据国家卫生健康委办公厅颁布的《质子泵抑制剂临床使用指导原则》,发起“质子泵抑制剂审方规则制订项

中文标题:

质子泵抑制剂审方规则专家共识

发布日期:

2022-04-26

简要介绍:

为进一步规范质子泵抑制剂的临床应用,为处方适宜性审核提供参考,重庆市医院协会药事管理专业委员根据国家卫生健康委办公厅颁布的《质子泵抑制剂临床使用指导原则》,发起“质子泵抑制剂审方规则制订项目”。该项目由陆军军医大学第一附属医院牵头,联合国内多家医疗机构的临床专家、药学专家和循证专家等,针对质子泵抑制剂的适应证、用法用量、特殊人群用药及药物相互作用等重点审核内容进行了研讨,最终形成了本共识。共识的主要内容包括奥美拉唑、艾司奥美拉唑、泮托拉唑、雷贝拉唑、兰索拉唑和艾普拉唑(均包括注射剂和口服制剂,按通用名计)的基础审方规则,并在此基础上针对基础审方规则未涵盖的部分临床应用情形形成了12条审方推荐意见,以期为各级医疗机构提供参考。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=质子泵抑制剂审方规则专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1011b1c002a228ee, title=质子泵抑制剂审方规则专家共识, enTitle=, guiderFrom=中国药房, authorId=0, author=, summary=为进一步规范质子泵抑制剂的临床应用,为处方适宜性审核提供参考,重庆市医院协会药事管理专业委员根据国家卫生健康委办公厅颁布的《质子泵抑制剂临床使用指导原则》,发起“质子泵抑制剂审方规则制订项, cover=https://img.medsci.cn/20220426/1650982799122_5579292.png, journalId=0, articlesId=null, associationId=2657, associationName=重庆市医院协会药事管理专业委员会, associationIntro=重庆市医院协会药事管理专业委员会, copyright=0, guiderPublishedTime=Tue Apr 26 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">为进一步规范质子泵抑制剂的临床应用,为处方适宜性审核提供参考,重庆市医院协会药事管理专业委员根据国家卫生健康委办公厅颁布的《质子泵抑制剂临床使用指导原则》,发起&ldquo;质子泵抑制剂审方规则制订项目&rdquo;。该项目由陆军军医大学第一附属医院牵头,联合国内多家医疗机构的临床专家、药学专家和循证专家等,针对质子泵抑制剂的适应证、用法用量、特殊人群用药及药物相互作用等重点审核内容进行了研讨,最终形成了本共识。共识的主要内容包括奥美拉唑、艾司奥美拉唑、泮托拉唑、雷贝拉唑、兰索拉唑和艾普拉唑(均包括注射剂和口服制剂,按通用名计)的基础审方规则,并在此基础上针对基础审方规则未涵盖的部分临床应用情形形成了12条审方推荐意见,以期为各级医疗机构提供参考。&nbsp;</span></p>, tagList=[TagDto(tagId=1835, tagName=质子泵抑制剂)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=20791, appHits=108, showAppHits=0, pcHits=371, showPcHits=20683, likes=2, shares=22, comments=4, approvalStatus=1, publishedTime=Wed Apr 27 15:18:00 CST 2022, publishedTimeString=2022-04-26, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Apr 26 22:22:04 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 18:06:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=质子泵抑制剂审方规则专家共识.pdf)])
质子泵抑制剂审方规则专家共识.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1249509, encodeId=b1de124950968, content=<a href='/topic/show?id=02f99235e23' target=_blank style='color:#2F92EE;'>#质子泵抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92357, encryptionId=02f99235e23, topicName=质子泵抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 06:29:11 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226294, encodeId=04f7122629400, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14408199438, createdName=ms4000000034336854, createdTime=Tue Jun 14 00:02:05 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217863, encodeId=5195121e86372, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a155600872, createdName=ms6000000298623125, createdTime=Sun May 08 15:35:59 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1249509, encodeId=b1de124950968, content=<a href='/topic/show?id=02f99235e23' target=_blank style='color:#2F92EE;'>#质子泵抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92357, encryptionId=02f99235e23, topicName=质子泵抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 06:29:11 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226294, encodeId=04f7122629400, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14408199438, createdName=ms4000000034336854, createdTime=Tue Jun 14 00:02:05 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217863, encodeId=5195121e86372, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a155600872, createdName=ms6000000298623125, createdTime=Sun May 08 15:35:59 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-06-14 ms4000000034336854

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1249509, encodeId=b1de124950968, content=<a href='/topic/show?id=02f99235e23' target=_blank style='color:#2F92EE;'>#质子泵抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92357, encryptionId=02f99235e23, topicName=质子泵抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 06:29:11 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226294, encodeId=04f7122629400, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14408199438, createdName=ms4000000034336854, createdTime=Tue Jun 14 00:02:05 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217863, encodeId=5195121e86372, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a155600872, createdName=ms6000000298623125, createdTime=Sun May 08 15:35:59 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-05-08 ms6000000298623125

    受益了

    0